title: Efficacy of vinorelbine-based neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis of randomized controlled trials.
abstract: The present study aimed to compare the effects of vinorelbine-based neoadjuvant chemotherapy and vinorelbine-free regimens. A meta-analysis of all the relevant randomized controlled trials was performed to investigate the improvement in pathological complete response (pCR), overall response rate (ORR) and breast-conserving surgery (BCS). The PubMed and Embase databases were searched for relevant studies reporting randomized controlled trials comparing vinorelbine-based neoadjuvant chemotherapy with vinorelbine-free regimens until July 2013. Risk ratios/odds ratio and 95% confidence intervals (CIs) were used to estimate the association between vinorelbine in neoadjuvant chemotherapy and various efficacy outcomes. Fixed- or random-effect models were adopted to pool the data. Five eligible studies with a total of 1,495 patients were included in the meta-analysis. Compared to vinorelbine-free chemotherapy, vinorelbine-based regimens demonstrated no significant improvement in clinical outcomes including: pCR [relative risk (RR)=1.016; 95% CI, 0.738-1.399; P=0.922], ORR (RR=1.048; 95% CI, 0.969-1.133; P=0.239) and BCS (RR=1.764; 95% CI, 0.734-4.239; P=0.205). However, vinorelbine-based regimens were associated with a lower incidence of grade 3-4 alopecia (OR, 0.617; 95% CI, 0.448-0.848; P=0.003). In a hierarchical analysis for patients who received neoadjuvant chemotherapy, the proportion of subjects achieving pCR was significantly increased when HER2-amplified (RR=2.31; 95% CI, 1.20-4.43; P=0.01) and hormone receptor negative (RR=0.488; 95% CI, 0.263-0.908; P=0.023). The present review confirms that neoadjuvant chemotherapy vinorelbine-based regimens are unlikely to emerge as superior to pCR, ORR and BCS. Hierarchical analysis indicated that the HER2-amplified and hormone receptor-negative patients were significantly associated with a pathological response rate.
authors.affiliation: Department of Breast Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi 530001, P.R. China.
authors.forename: Hui
authors.initials: H
authors.lastname: Gao
authors.affiliation: Department of Breast Surgery, The Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
authors.forename: Qiuyun
authors.initials: Q
authors.lastname: Li
authors.affiliation: Department of Breast Surgery, The Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.affiliation: Department of Breast Surgery, The Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
authors.forename: Y I
authors.initials: YI
authors.lastname: Jiang
authors.affiliation: Department of Breast Surgery, The Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
authors.forename: Huawei
authors.initials: H
authors.lastname: Yang
authors.affiliation: Department of Breast Surgery, The Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
authors.forename: Jianlun
authors.initials: J
authors.lastname: Liu
keywords: breast cancer; meta-analysis; neoadjuvant chemotherapy; vinorelbine